GLP-1's Weekly Pills Pens and Progress 6
Posted on September 1, 2026 by Sally-Anne Turner
GLP-1’s Weekly Pills Pens and Progress 6
Next month in the UK, it is highly likely that we will welcome the Eli Lilly pill, Foundayo, into our GLP-1 family at the Bodyline Clinic. This drug will allow us to offer a different solution to our customers, who may not get the results that they want with the Wegovy pill, making this a time to celebrate!
Of course, GLP-1 news doesn’t stop there. The world of clinical research is never dull, and here, we have pulled together some interesting insights into what’s been happening globally with GLP-1s. So read on and enjoy GLP-1’s Weekly from the Bodyline Clinic.
Novo Nordisk Injectable Findings from Phase 2 Trial
OK, so by this point, most people who are looking into GLP-1 medications have heard of Novo Nordisk.
The results of a phase 2 trial that was funded by the pharmaceutical giant have been investigating zenagamtide. This is a GLP-1drug that also activates amylin and calcitonin receptors in adults who have type 2 diabetes. This medication is weekly, injectable and has taken place across 83 sites in 11 countries. So, it’s big!
Now, the study looked at this drug over 36 weeks, with 262 people receiving it. 225 received zenagamtide and 37 received placebos. The dose range was 0.4mg to 40mg with the dose increased monthly.
At 36 weeks, the blood sugar (HbA1c) was reduced by 1.7% in the group receiving zenagamtide. The weight loss was also noted, with participants having an estimated 14.6% reduction in body weight after 46 weeks, at the 40mg dose.
Of course, it’s a GLP-1, so there were some side effects, with the most common being gastrointestinal. These were considered mild to moderate and, like other GLP-1’s, occurred when the doses were escalated. 8% of the participants (21 people) experienced serious effects, but the results are supporting progression to phase 3.
So, this drug may be joining the GLP-1 family in the next few years!
See the original research paper here— Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial - PubMed
AstraZeneca’s Oral GLP-1 Elecoglipron
Another major player in the GLP-1 field has released the results of their VISTA Phase 2b trial.
AstraZeneca has been looking into an investigational drug called elecoglipron. This is a GLP-1 receptor agonist, which is oral and needs to be taken daily. This study looked at 2310 adults who were either diagnosed as overweight or obese over 36 weeks. It examined their blood sugar levels alongside their overall percentage weight loss.
Compared to the placebo group, those taking elecoglipron:
- Lost 10.5 % of their body weight at 26 weeks, at the 75mg dose.
- Lost 11.8% of their body weight at 36 weeks.
This medication was also used in the SOLSTICE trial, which had 404 participants who had type 2 diabetes. In this study of elecoglipron, after 26 weeks, blood sugar had fallen by 1.9%.
So, it seems that with this GLP-1, the average weight loss is around the same as other oral GLP-1’s. However, the impact on blood sugar is a core difference, which may (hopefully) make type 2 diabetes management easier in the future.
See the original papers here:
Found Retatrutide in the UK? Don’t Take It!
OK, so in the run-up to the release of the Eli Lilly pill Foundayo in the UK, there has been a spike in people searching for Retatrutide online. Probably because they have the same manufacturer.
However, unlike Foundayo, which has been subject to multiple clinical trials and has now been given MHRA approval in the UK, Retatrutide has not. In fact, at the time of writing, Retatrutide has not been deemed safe for use in humans and is still in the clinical trial stages.
A bit about this drug. It’s a triple hormone receptor agonist. So, it activates GLP-1, GIP, and glucagon, making it different from all of the other weight loss options on the market. Indeed, it has been named the “Godzilla” of weight loss medications as, in the Phase 3 TRIUMPH-4 trial, those who were taking the 12mg maintenance dose, achieved a mean reduction in body weight of 28.7% over 68 weeks. That kind of weight loss has only ever been seen in bariatric surgery.
It’s easy to see the appeal for those who may have tried diet and exercise. But if you see Retatrutide for sale online, please don’t buy or take it. It’s illegal and is guaranteed to be a scam. It isn’t Retatrutide and injecting it into yourself could make you extremely sick.
Two major providers of these “Retatrutide” medications are companies Synedica and Alluvi. Both say that this medication is for research only, but they are clearly pointing sales at the public. Avoid them at all costs!
So, if you found Retatrutide on TikTok and have bought it, don’t take it. Report it to the MHRA immediately and seek medical guidance for any concerns you may have relating to weight loss.
At the time of writing, the TRIUMPH 4 paper is not available online. There is an overview from the Eli Lilly site here: Lilly’s triple agonist, Retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company
When the full paper comes online, we will let you know!
If you have any concerns about your weight loss journey, our team at the Bodyline Clinic may be able to help. We have over 18 years of experience with people who want to reach their weight loss goals and we know how hard it can be online to spot fake weight loss drugs. So, if you want to lose weight safely and with clinical expertise backing your journey, contact us today.
